

(19)

Europäisches Patentamt
European Patent Office
Office européen des brevets



(11) **EP 1 034 787 A1**

(12)

EUROPEAN PATENT APPLICATION

(43) Date of publication:
13.09.2000 Bulletin 2000/37

(51) Int Cl.7: **A61K 35/74, C12N 1/20,**
A23L 1/29, A23C 9/152
// (C12N1/20, C12R1:225)

(21) Application number: 99104922.2

(22) Date of filing: 11.03.1999

(84) Designated Contracting States:
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU
MC NL PT SE
Designated Extension States:
AL LT LV MK RO SI

- **Reniero, Roberto**
1801 Le Mont-Pelerin (CH)
- **Servin, Alain, UFR de Sc. Ph. Paris XI**
92296 Chatenay-Malabry (FR)

(71) Applicant: **Société des Produits Nestlé S.A.**
1800 Vevey (CH)

(74) Representative: **Becker Kurig Straus**
Patentanwälte
Bavariastrasse 7
80336 München (DE)

(72) Inventors:
• **Neeser, Jean-Richard**
1073 Savigny (CH)

(54) **Lactobacillus strains preventing diarrhea caused by pathogenic bacteria**

(57) The present invention pertains to novel microorganisms of the genus *Lactobacillus*, that are useful in preventing diarrhea brought about by pathogenic bac-

teria. In particular, the present invention relates to the use of said microorganisms for the preparation of an ingestible support and to a composition containing the same.

Nestlé Research Centre



Inhibition of adhesion of enterovirulent *E. coli* during the contact with the bacterial culture NCC2461




Fig.1

EP 1 034 787 A1

Description

[0001] The present invention pertains to novel microorganisms of the genus *Lactobacillus*, that are useful in preventing diarrhea brought about by pathogenic bacteria. In particular, the present invention relates to the use of said microorganisms for the preparation of an ingestible support and to a composition containing the same.

[0002] Organisms that produce lactic acid as a major metabolic component have been known for a long time. These bacteria may be found in milk or in milk processing factories, respectively, living or decaying plants but also in the intestine of man and animals. These microorganisms, summarized under the term "lactic acid bacteria", represent a rather inhomogeneous group and comprise e.g. the genera *Lactococcus*, *Lactobacillus*, *Streptococcus*, *Bifidobacterium*, *Pediococcus* etc..

[0003] Lactic acid bacteria have been utilized as fermenting agents for the preservation of food taking benefit of a low pH and the action of fermentation products generated during the fermentative activity thereof to inhibit the growth of spoilage bacteria. To this end, lactic acid bacteria have been used for preparing a variety of different foodstuff such as cheese, yogurt and other fermented dairy products from milk.

[0004] Quite recently lactic acid bacteria have attracted a great deal of attention in that some strains have been found to exhibit valuable properties to man and animals upon ingestion. In particular, specific strains of the genus *Lactobacillus* or *Bifidobacterium* have been found to be able to colonize the intestinal mucosa and to assist in the maintenance of the well-being of man and animal.

[0005] In this respect, EP 0 768 375 discloses specific strains of the genus *Bifidobacterium*, that are capable to become implanted in the intestinal flora and may adhere to intestinal cells. These *Bifidobacteria* are reported to assist in immunomodulation, being capable to competitively exclude adhesion of pathogenic bacteria to intestinal cells, thus assisting in the maintenance of the individual's health.

[0006] During the last few years research has also focused on the potential use of lactic acid bacteria as probiotic agents. Probiotics are considered to be viable microbial preparations which promote the individual's health by preserving the natural microflora in the intestine. A microbial preparation may be commonly accepted as a probiotic in case the effectual microbes thereof and their mode of action are known. Probiotics are deemed to attach to the intestine's mucosa, colonize the intestinal tract and likewise prevent attachment of harmful microorganisms thereon. A crucial prerequisite for their action resides in that they have to reach the gut's mucosa in a proper and viable form and do not get destroyed in the upper part of the gastrointestinal tract, especially by the influence of the low pH prevailing in the stomach.

[0007] In this respect, WO 97/00078 discloses a specific strain, termed *Lactobacillus* GG (ATCC 53103), as such a probiotic. The microorganism is particularly employed in a method of preventing or treating food induced hypersensitivity reactions in that it is administered to a recipient together with a food material that has been subjected to a hydrolysis treatment with pepsin and/or trypsin. The *Lactobacillus* strain selected is described as exhibiting adhesive and colonizing properties and showing a protease enzyme system, so that the protein material contained in the foodstuff to be administered is further hydrolyzed by means of proteases secreted by the specific *Lactobacillus* strain. The method discussed in this document shall eventually result in the uptake of protein material by the gut that does not show a substantial amount of allergenic material anymore.

[0008] Further, in EP 0 577 903 reference is made to the use of such lactic acid bacteria having the ability of replacing *Helicobacter pylori*, the acknowledged cause for the development of ulcer, in the preparation of a support intended for the therapeutic or prophylactic treatment of an ulcer associated with the action of *Helicobacter pylori*.

[0009] In knowledge of the valuable properties particular strains of lactic acid bacteria may provide, there is a desire in the art for additional lactic acid bacterial strains that are beneficial to the well being of man and/or animal.

[0010] Consequently, a problem of the present invention is to provide additional bacterial strains that exhibit new properties beneficial for man and/or animals.

[0011] The above problem has been solved by providing novel microorganisms, namely lactic acid bacteria, belonging to the genus *Lactobacillus* having the capability of preventing colonization of the intestine with pathogenic bacteria causing diarrhea.

[0012] According to a preferred embodiment the *Lactobacillus* strain is capable of adhering to the intestinal mucosa of mammal and may grow in the presence of up to 0.4 % bile salts.

[0013] Yet, according to another preferred embodiment the lactic acid bacterium is selected from the group consisting of *Lactobacillus rhamnosus* or *Lactobacillus paracasei*, preferably *Lactobacillus paracasei*, and is more preferably *Lactobacillus paracasei* CNCM I-2116.

[0014] The microorganisms of the present invention have been shown to exhibit inter alia the following properties: they are gram positive, catalase negative, NH_3 form arginine negative and CO_2 production negative, they produce L (+) lactic acid, are capable to grow in the presence of bile salts in a concentration of up to about 0.4 % and may essentially prevent colonization of intestinal cells by bacteria bringing about diarrhea, such as pathogenic *E. coli*, e.g. enteropathogenic *E. coli* (EPEC), or salmonella, e.g. salmonella typhimurium.

[0015] The novel microorganisms may be used for the preparation of a variety of ingestible support materials, such as e.g. milk, yogurt, curd, fermented milks, milk based fermented products, fermented cereal based products, milk based powders, infant formulae and may be included in the support in an amount of from about 10^5 cfu / g to about 10^{11} cfu / g. For the purpose of the present invention the abbreviation cfu shall designate a "colony forming unit" that is defined as number of bacterial cells as revealed by microbiological counts on agar plates.

[0016] The present invention also provides a food or a pharmaceutical composition containing at least one of the Lactobacillus strains having the above traits and/or containing a supernatant of a culture, in which the microorganisms have been grown or a fraction thereof, respectively.

[0017] For preparing a food composition according to the present invention at least one of the Lactobacillus strains of the present invention is incorporated in a suitable support, in an amount of from about 10^5 cfu / g to about 10^{11} cfu / g, preferably from about 10^6 cfu / g to about 10^{10} cfu / g, more preferably from about 10^7 cfu / g to about 10^9 cfu / g.

[0018] In case of a pharmaceutical preparation the product may be prepared in forms of tablets, liquid bacterial suspensions, dried oral supplements, wet oral supplements, dry tube feeding or a wet tube feeding with the amount of Lactobacillus strains to be incorporated therein being in the range of up to about 10^{12} cfu / g, preferably from about 10^7 cfu / g to about 10^{11} cfu / g, more preferably from about 10^7 cfu / g to about 10^{10} cfu/g.

[0019] The activity of the novel microorganisms in the individual's intestine is naturally dose dependent. That is, the more the novel microorganisms are incorporated by means of ingesting the above food material or the pharmaceutical composition the higher the protective and/or curing activity of the microorganisms. Since the novel microorganisms are not detrimental to mankind and animals and have eventually been isolated from baby feces a high amount thereof may be incorporated so that essentially a high proportion of the individual's intestine will be colonized by the novel microorganisms.

[0020] Yet, according to another preferred embodiment the supernatant of a culture of a Lactobacillus strain of the present invention may be used for preparing one of the above ingestible support. The supernatant may be used as such or may well be dried under conditions that do not destroy the metabolic compounds secreted by the microorganisms into the liquid medium, such as e.g. freeze drying, and may be included in the carrier. In order to minimize the number of unknown compounds in the supernatant the Lactobacilli strains will preferably be grown in a defined media, the composition of which is known and does not negatively affect the host incorporating it. Further, the skilled person will, based on his general knowledge optionally deplete the supernatant from unwanted products, such as e.g. by means of chromatography.

[0021] In the figures,

[0022] Fig. 1 shows a scheme illustrating the results of a cell culture experiment in which cultured ST11 cells were used in an assay for inhibiting adhesion of pathogenic E. coli bacteria to epithelial cells.

[0023] Fig. 2 shows a scheme illustrating the results of a cell culture experiment, in which the supernatant of a ST11 culture was used in an assay for inhibiting adhesion of pathogenic E. coli bacteria to epithelial cells.

[0024] Fig. 3 shows a scheme illustrating the results of a cell culture experiment, in which cultured ST11 cells were used in an assay for inhibiting invasion of salmonella typhimurium into epithelial cells.

[0025] Fig. 4 shows a scheme illustrating the results of a cell culture experiment, in which the supernatant of a ST11 culture was used in an assay for inhibiting invasion of salmonella typhimurium into epithelial cells.

[0026] Fig. 5 shows the acidification of the L. casei strain CNCM I-2116 (termed ST11) in different growth media.

[0027] Fig. 6 shows the survival rate of the L. casei strain ST11 at 10°C measured during 30 days.

[0028] Fig. 7 shows the mRNA pattern of IL-12 and IL-10 in mouse adherent cells derived from bone marrow after incubation of the cells with serial dilutions of ST11.

[0029] Fig. 8 shows the outcome of Th2 differentiation as resulting in decreased IL-4 production.

[0030] During the extensive studies leading to the present invention the inventors have investigated baby feces and isolated a variety of different bacterial strains therefrom. These strains were subsequently examined for their capability to prevent colonization of epithelial cells with bacteria that are known to cause diarrhea.

[0031] Several bacterial genera comprising Lactobacillus, Lactococcus and Streptococcus were screened for their diarrhea inhibitory properties. The tests for the inhibitory property were essentially performed with pathogenic E. coli and salmonella typhimurium as representative for pathogenic microorganisms causing diarrhea in an affected individual.

[0032] The various lactic acid bacteria were grown in a suitable medium, such as MRS, Hugo-Jago or M17 medium at temperatures of from about 30 to 40°C corresponding to their optimal growth temperature. After reaching stationary growth the bacteria were collected by centrifugation and resuspended in physiological NaCl solution. Between the different tests the bacterial cells were stored frozen (-20°C).

[0033] For assessing anti-bacterial properties the following approaches were chosen.

[0034] According to one protocol cultured Lactobacillus strains of the present invention were examined for their capability to prevent adhesion of pathogenic bacteria causing diarrhea to intestinal cells or invasion thereof into intestinal cells, respectively. To this end, intestinal cells were contacted with the pathogenic bacteria and the cultured Lacto-

bacillus strains of the present invention, and the rate of adhesion, or invasion, respectively, was assessed.

[0035] According to a second protocol the supernatant of a cell culture of the *Lactobacillus* strains of the present invention was added together with the pathogenic microorganisms to the intestinal cells and the rate of adhesion, or invasion, respectively, was assessed.

[0036] Thus, it could be shown that the cultured *Lactobacilli* and the supernatant proved to be extremely effective to prevent both adhesion to and invasion into the intestinal cells indicating that metabolic compounds secreted by the novel microorganisms are likely to be responsible for the anti-diarrhea activity.

[0037] In addition to the above finding it could also be shown that the strains of the present invention surprisingly also exhibit anti-allergenic properties in that said strains have an impact on the synthesis of different immunological mediators.

[0038] It is generally acknowledged that humoral immune responses and allergic reactions are mediated by CD4⁺ T cells bearing the type 2 phenotype (Th2). Th2-cells are characterized by the production of high levels of interleukin 4 (IL-4), a cytokine required for the secretion of IgE, which is the major antibody class involved in allergic reactions.

[0039] The differentiation of Th2 cells is impaired by IFN- γ , a particular cytokine that is produced by the mutually exclusive Th1 subset of CD4⁺ T cells. Said Th1 cells are in turn strongly induced by interleukin 12 (IL-12). In contrast thereto IL-10, another cytokine, has been shown to have a strong suppressing impact on the proliferation of Th1 cells and is therefore deemed to play a role in immuno-suppressive mechanisms.

[0040] In summary, both IL-12 and IL-10 have strong modulatory effects on CD4⁺ T cell development by influencing the development of the Th1 subset. IL-12 is a key regulatory cytokine for the induction of Th1 differentiation and thus inhibits the generation of Th2 responses. A major pathway for inhibition of Th2 cells is therefore seen in the stimulation of IL-12 synthesis by accessory cells.

[0041] It is well known that some components of gram negative bacteria, such as LPS, induce high levels of IL-12 in adherent cells, such as macrophages and dendritic cells. Consistently, it has been found that gram negative bacteria can strongly bias CD4⁺ T cell differentiation towards the Th1 phenotype.

[0042] The microorganism ST11 as an example of the *Lactobacillus* strains of the present invention has been tested for a potential role in the induction of cytokines involved in the regulation of CD4⁺ T cell differentiation. In particular, the effect of ST11 on the phenotype of CD4⁺ T cells undergoing Th2 differentiation has been studied.

[0043] In this respect the capacity of ST11 to induce the synthesis of mRNA encoding these two regulatory cytokines in mouse adherent cells derived from bone marrow was compared with 4 other strains of *Lactobacilli* and with a control of gram negative bacteria (*E. coli* K12). The mRNA was measured by semi-quantitative RT-PCR after 6 hours of incubation of the cells with serial dilutions of bacteria ranging from 10^7 to 10^9 cfu/ml.

[0044] Although all strains of *Lactobacillus* could induce transcription of IL-12 mRNA to a certain degree, ST11 could be shown to be the strongest inducer, since as a strong PCR signal could be detected even at the lowest bacterial dose. In fact, the capacity of ST11 to induce IL-12 mRNA transcription was as strong as that of *E. coli*. Induction of IL-10 mRNA was in general weaker than for IL-12 mRNA, as only at higher bacterial doses a signal could be detected. Nevertheless, ST11 was the strongest inducer of IL-10 mRNA, as compared to the other *Lactobacilli* and the *E. coli* control.

[0045] Thus, ST11 is deemed to be efficient in inducing immunoregulatory cytokines involved in CD4⁺ T cell differentiation. Its strong capacity to induce IL-12 makes it a candidate to inhibit Th2 responses and its measurable IL-10 induction may prevent inflammatory responses.

[0046] In addition to the above finding it was also determined whether ST11 had an inhibitory effect on CD4⁺ T cells undergoing Th2 differentiation and a positive effect on Th1 functions. A well established cell differentiation culture system was utilized, where precursor CD4⁺ T cells were polyclonally activated and modulated to undergo either Th1 or Th2 differentiation, depending on the type of co-stimuli provided in the culture medium. Th1/Th2 differentiation was induced during a 7-days primary culture, after which the cells were then restimulated for 2 days in a secondary culture containing medium alone and acquisition of a specific phenotype (Th1 or Th2) was assessed by measuring the types of cytokines produced in the supernatant (IFN- γ vs. IL-4).

[0047] It is generally known that precursor CD4⁺ T cells from mice of the BALB/c background preferentially differentiate to predominant Th2 phenotype (high IL-4, low IFN- γ in the 2ry culture supernatants) after activation under neutral conditions (medium alone in the 1ry culture). This phenotype could be completely reverted to a Th1 pattern (high IFN- γ , low IL-4) upon addition of a blocking monoclonal antibody to IL-4 in the 1ry culture.

[0048] To investigate a potential role for ST11 on Th2 inhibition, purified precursor CD4⁺ T-cells from BALB/c mice were activated in the presence of bone marrow adherent cells as accessory cells during the 1ry culture. These cells were co-cultured either in medium alone, or in the presence of 1 mg/ml LPS, or 10^8 cfu/ml ST11, or 10^8 cfu/ml of another *Lactobacillus*. After this time, the cells were washed and CD4⁺ T cells were purified once again and restimulated in the 2ry culture in medium alone.

[0049] Cytokines produced by the differentiated CD4⁺ T cells were measured after 2 days. As expected, cells that differentiated in the presence of medium alone displayed a dominant Th2 phenotype. Addition of ST11 to the 1ry

cultures strongly modulated the outcome of Th2 differentiation, as it resulted in an 8-fold decrease in IL-4 production. This inhibition was of similar magnitude as that observed in cultures derived from cells differentiated in the presence of LPS. In contrast thereto, the other Lactobacillus strain had no measurable impact on IL-4 levels. Interestingly, IFN- γ levels were not increased upon addition of ST11 in the 1ry cultures.

[0050] In summary, ST11 specifically impaired IL-4 production by CD4⁺ T cells undergoing Th2 differentiation, but did not significantly increase IFN- γ secretion. The fact that ST11 does not increase IFN- γ production may be due to its capacity to induce IL-10 with the consequence that it may keep a low inflammatory impact despite its anti-Th2 activity.

[0051] In consequence, it could be shown that ST11 is one of Lactobacillus strains that have a good anti-Th2 profile which makes them excellent candidates for their use as a bacterium with anti-allergic, probiotic activity.

[0052] The present invention will now be described by way of examples without limiting the same thereto.

Media and solutions:

[0053]

MRS (Difco)

Hugo-Jago (tryptone 30g / l (Difco), yeast extract 10 g / l (Difco), lactose 5 g / l (Difco), KH_2PO_4 6 g / l, beef extract 2 g / l (Difco), agar 2 g / l (Difco))

M17 (Difco)

DMEM (Dulbecco's modified Eagle medium)

CFA (according to Ghosh et al. Journal of Clinical Microbiology, 1993 31 2163-6)

Müller Hinton agar (Oxoid)

LB (Luria Bertami, Maniatis, A Laboratory Handbook, Cold Spring Harbor, 1992)

Antibiotics were obtained from Sigma

C^{14} -acotato (53,4 Ci/mMol, Amersham International PLC)

PBS (NaCl 8g/l, KCl 0.2 g/l, Na_2HPO_4 1.15 g/l, KH_2PO_4 0.2 g/l)

Trypsin-EDTA solution (Seromed)

FCS Fetal calf serum (Gibco)

[0054] E. coli DAEC C 1845 was obtained from Washington University, Seattle and E. coli JPN15 was obtained from the Center for Vaccine Development of the University of Maryland, USA). The salmonella typhimurium strain SL1344 was obtained from the department of microbiology, Stanford University, CA, USA).

Example 1

Isolation of lactic acid bacteria from baby feces

[0055] Fresh feces were harvested from diapers of 16 healthy babies 15 to 27 days old. 1 g of fresh feces was placed under anaerobic conditions for transportation to the laboratory and microbiological analyses were run within 2 hours from sampling by serial dilutions in Ringer solution and plating on selective media. MRS agar plus antibiotics (phosphomycin 80 $\mu\text{g}/\text{ml}$, sulfamethoxazole 93 $\mu\text{g}/\text{ml}$, trimethoprim 5 $\mu\text{g}/\text{ml}$) incubated at 37°C for 48 hours was used to isolate lactic acid bacteria. Colonies were randomly picked up and purified. Physiological and genetic characterization was performed on the isolates.

Example 2

Cultivating Caco-2 cells

[0056] For the inhibition assays the cell line Caco-2 was utilized as a model of the intestine. This cell line presents features characteristic for intestinal cells such as e.g. polarisation, expression of intestinal enzymes, production of particular structural polypeptides etc..

[0057] The cells were grown on three different supports, namely on plastic dishes (25 cm², Corning) for growth and propagation, on defatted and sterilized 6 well glass plates (22 x 22 mm, Corning) for the adhesion tests, and on 24 well glass plates (Corning) for the inhibition tests.

[0058] After the second day in culture the medium (DMEM) was changed on a daily basis. Before use the medium was supplemented with 100 U/ml penicilline / streptomycine, 1 $\mu\text{g}/\text{ml}$ amphotericine and 20 % FCS inactivated at 56 ° for 30 min. Culturing was performed at 37 °C in an atmosphere comprising 90% air and 10% CO_2 . The cells were splitted every six days. The cells were detached from the walls of the well by treatment in PBS with 0.25 % trypsin and

3 mM EDTA at pH 7.2. For neutralizing the effect of trypsin an equal volume of FCS was added to the cell suspension obtained, the mixture was centrifuged (10 min at 1000 rpm) and the pellet was again put in culture. About 3.5×10^5 cells were transferred to a new culture bottle and cultivated until a confluent monolayer was obtained.

5 Example 3

Cultivating bacteria

ST11:

10 [0059] The bacterial strain has been stored at -20 °C in MRS medium containing 15 % glycerol. The strain has been grown under anaerobic conditions in MRS and transferred twice to new media at intervals of 24 hours before use in the inhibition assays. For the assay a concentration of 2×10^9 cfu/ml was utilized.

15 [0060] The supernatant was collected by centrifugation for 1 hour at 20.000 rpm and the supernatant obtained was subsequently checked for the presence of bacteria.

E. coli:

20 [0061] Two E. coli strains were used, E. coli DAEC C 1845 (Diffuse Adhesion E. Coli) and E. coli JPN15 (EPEC; Enteropathogenic E. Coli).

[0062] The first passage after thawing was effected on a CFA - Müller Hinton agar, which is suitable to effect expression of adhesion factors by the bacterium.

25 [0063] Before each experiment the bacterial cells were incubated at 37 °C with a transfer to a new medium being effected twice after 24 hours each. Since JPN15 contains the gene for ampicilline resistance said antibiotic was used for selection during growth.

Salmonella:

30 [0064] The salmonella typhimurium strain SL1344 was utilized for the experiments, which was grown before usage in LB medium.

Example 4

Inhibition assay for E. coli

35 [0065] After the second passage to new medium the pathogenic bacterial strains were marked with radioisotopes using C^{14} -acetat at 10 μ Ci/ml in LB-medium. Incubation of the strains in this medium was performed for 18 hours at 37 °C.

40 [0066] The bacterial suspension was subsequently subjected to centrifugation (1041 g, 15 min) so as to eliminate the supernatant with the remaining C^{14} -acetate. The pellet was suspended and washed in PBS and the cells were suspended at a concentration of about 10^8 cells / ml in 1 % sterile mannose. The mannose is known to inhibit non specific adhesion.

45 [0067] The different pathogenic bacterial strains (E. coli) were contacted with a monolayer of the Caco-2 cells (37 °C, 10 % CO_2 , 90 % air) for 3 hours. The same experiments were carried out using supernatant (obtained by centrifuging at 20.000 rpm for 40 min).

[0068] As a control the pathogenic bacteria were contacted with the Caco-2 monolayer without concurrent addition of ST11 or a culture supernatant, respectively.

50 [0069] After 3 hours incubation the medium was changed and the monolayer was washed three times with PBS. Each washing step included 20 x stirring of the PBS solution so as to eliminate essentially all of non specific adhesion. The cells were lysed thereafter by addition of 1 ml sodium carbonate and incubation for 40 min at 37 °C. After homogenization an aliquot (250 μ l) was diluted in 5 ml scintillation fluid (Hionic-fluor Packard) and counted (Packard 2000). The percentage of the adhesion of pathogenic cells to Caco-2 cells was calculated against the control, which was set to 100 % (adhesion; or invasion for example 5).

Example 5**Inhibition assay for salmonella**

[0070] Salmonella are bacteria that invade epithelial cells and multiply therein. For determining the inhibitory activity of ST11 salmonella typhimurium strain SL1344 was incubated as described above in a medium containing ^{14}C -acetate and was subjected to the experiment described in example 4.

[0071] After incubation the Caco-2 cells were washed with PBS so as to eliminate all non-adhering cells. Subsequently medium was added containing gentamycin (20 $\mu\text{g/ml}$) and incubation was continued for 1 hour at 37 °C. Gentamycin is an antibiotic not penetrating intestinal cells so that all extracellular microorganisms were killed, while salmonella having already invaded intestinal cells will survive. After washing the cells twice with PBS the cells were lysed by addition of sterile distilled water and the radioactivity was measured as described in example 4.

[0072] The results of experiments 4 and 5 are shown in figures 1 to 4. It may be seen that cultured ST11 cells and the culture supernatant were extremely effective in preventing adhesion of and invasion into intestinal cells by pathogenic microorganisms causing diarrhea.

Example 6**Properties of ST11**

[0073] ST 11 has been subjected to incubation in simulated gastric juice. The simulated gastric juice was prepared by suspending pepsin (3 g/l) in sterile saline (0.5% w/v) and adjusting the pH to 2.0 and 3.0, respectively, with concentrated HCl. ST 11 has been grown in varying amounts in the above media and the resistance of the microorganisms has been determined.

[0074] The results are summarized in table I below.

Table I

pH	Cfu/ml at T 0	Cfu at T 1min	Cfu at T 15	cfu at T 30	cfu at T 60
2.0	2.0×10^9	1.8×10^9	1.2×10^9	3.7×10^8	7.0×10^3
3.0	2.0×10^9	1.9×10^9	1.7×10^9	1.7×10^9	8.4×10^8

[0075] ST11 has the following properties as defined according to methods disclosed in the genera of lactic acid bacteria, Ed. B.J.B. Wood and W.H. Holzapfel, Blackie A&P.

- gram positive,
- catalase negative,
- NH_3 form arginine negative
- CO_2 production negative
- production of L(+) lactic acid
- growth in the presence of bile salts in a concentration of up to about 0.4 %.

Example 7**Growth of ST 11 under different conditions**

[0076] ST11 was incubated at 37 °C in tomato based medium (4% tomato powder rehydrated in distilled water) supplemented with sucrose (0, 0.5, 1 or 2%) or soya peptone (0.5%) or glucose (0.5%) for different periods of time. The results are shown in fig. 5.

[0077] ST11 was further added in an amount of 2.5 % to a medium composed of rice flour (3%), wheat flour (2%) and sucrose (3%) and incubated at 37°C until a pH of 4.4 was reached. After cooling the product was packed with or without addition of vitamine C and stored at 10°C.

[0078] Fig. 5 shows survival data of ST 11 at 10°C in a cereal drink packed in different plastic materials (HDPE High density polyethylene, PS polystyrene).

Example 8**Induction of IL-12 and IL-10- mRNA synthesis in mouse adherent cells by ST11**

[0079] Bone marrow cells were isolated from the femur and tibia of 8 week-old specific pathogen-free C57BL/6 mice and were incubated at a concentration of 2×10^6 cells/ml in RPMI medium (Gibco) containing 10% fetal bovine serum, 1 mM L-Glutamine, 12 mM Hepes, 0.05 mM 2-mercaptoethanol, 100 U/ml penicillin and 100 µg/ml streptomycin (all reagents from Gibco) for 12 hours at 37°C in a 5% CO₂ atmosphere. Non-adherent cells were discarded by 3 consecutive washes with warm culture medium and the remaining adherent cells were harvested and incubated at a concentration of 10^6 cells/ml for 6 hours in the presence or absence of bacteria. It was previously determined that 6 hours represents an optimal time-point for cytokine mRNA synthesis by mouse adherent cells in response to LPS. Bacteria were added at different concentrations ranging from 10^9 to 10^7 cfu/ml. Bacteria were grown and stored as indicated above (page 6).

[0080] At the end of the 6-hour culture period, cells were isolated by centrifugation and lysed using the TRIzol reagent kit (GibcoBRL, Cat. No. 15596-018) following the manufacturer's instructions. Total RNA was isolated by isopropanol precipitation and reverse-transcribed into cDNA for 90 min at 42°C using 200 U reverse transcriptase (Superscript II, BRL) in a 40-µl reaction volume containing 200 mM Tris pH 8.3, 25 mM KCl, 1 µg/ml oligo d(T)₁₅ (Boehringer Mannheim), 1 mM DTT (Boehringer Mannheim), 4 mM of each dNTP (Boehringer Mannheim) and 40 U/ml Rnasin (Promega). PCR primers and conditions were used as already described in Kopf et al. (Journal of Experimental Medicine 1996 Sep 1;184(3):1127-36). Amounts of cDNA were normalized within the samples using primers specific for a house-keeping gene (β-2-microglobulin). PCR products were separated on a 2% agarose gel and bands were analyzed under UV.

[0081] As shown in Figure 7, ST11 showed the strongest induction of IL-12 and IL-10 mRNA, which was comparable to levels observed with the positive control (E. coli). Differences are best seen at the lowest bacteria concentrations (10^7 cfu/ml).

Example 9**Suppression of IL-4 synthesis by ST11**

[0082] CD4⁺ T cells were purified from the spleen of specific pathogen-free BALB/c mice using the MiniMACS kit from Miltenyi Biotec (Cat. No. 492-01). The CD4⁺ T cells were cultured at a concentration of 2×10^5 cells/ml in RPMI medium containing 10% fetal bovine serum, 1 mM L-Glutamine, 12 mM Hepes, 0.05 mM 2-mercaptoethanol, 100 U/ml penicillin and 100 µg/ml streptomycin and activated during one week by cross-linking with plate-bound monoclonal antibodies to CD3 (clone 2C11) and CD28 (clone 37.51, both antibodies from Pharmingen). During this 1ry culture, the CD4⁺ T cells were co-cultured with bone marrow adherent cells (isolated as described above) as accessory cells and with 10^8 cfu/ml ST11, or 10^8 cfu/ml La1, or 1 mg/ml LPS, or medium alone. After this time, the cells were washed and CD4⁺ T cells were purified once again using MiniMACS kit technology and restimulated in a 2ry culture containing medium alone. Cytokines produced by the differentiated CD4⁺ T cells were measured in the supernatants after 2 days using sandwich ELISA (kits from Endogen and Pharmingen).

[0083] Results are shown in Fig. 5. Cells differentiated in the presence of medium alone displayed a dominant Th2 phenotype characterized by high levels of IL-4. Addition of ST11 to the 1ry cultures strongly modulated the outcome of Th2 differentiation, as it resulted in an 8-fold decrease in IL-4 production. This inhibition was of similar magnitude as that observed in cultures derived from cells differentiated in the presence of LPS. In contrast thereto, the other Lactobacillus strain had no measurable impact on IL-4 levels. Interestingly, IFN-γ levels were not increased upon addition of ST11 in the 1ry cultures.

[0084] As may be seen from the above the strains of the present invention may be well prepared for the production of a food and/or a pharmaceutical carrier taking advantage of the valuable properties of the microorganisms.

Claims

1. Lactic acid bacterium strain belonging to the genus Lactobacillus having the capability of preventing colonization of the intestine with pathogenic bacteria causing diarrhea.
2. The Lactobacillus strain according to claim 1, which is capable of adhering to the intestinal mucosa of a host organism.

3. The *Lactobacillus* strain according to any of the preceding claims, which is capable to grow in the presence of up to 0.4 % bile salts.
4. The *Lactobacillus* strain according to any of the preceding claims, which is selected from the group consisting of *Lactobacillus rhamnosus* or *Lactobacillus paracasei*.
5. The *Lactobacillus* strain according to claim 4, which is *Lactobacillus paracasei*.
6. The *Lactobacillus paracasei* according to claim 5, which is *Lactobacillus paracasei* CNCM I-2116.
7. Use of a *Lactobacillus* strain according to any of the preceding claims for the preparation of an ingestible support material.
8. The use according to claim 7, wherein the *Lactobacillus* strain is contained in the support material in an amount from about 10^5 cfu / g to about 10^{12} cfu / g support material.
9. Use of a supernatant of a culture of a *Lactobacillus* strain according to any of the claims 1 to 6 for the preparation of an ingestible support
10. The use according to any of the claims 7 or 9, wherein the support material is a food composition selected from milk, yogurt, curd, cheese, fermented milks, milk based fermented products, ice-creams, fermented cereal based products, milk based powders, infant formulae.
11. The use according to any of the claims 7 to 10, wherein the support material is used for the treatment and/or prophylaxis of disorders associated with diarrhea.
12. Food or pharmaceutical composition containing at least one *Lactobacillus* strain according to any of the claims 1 to 6 or a supernatant of a culture thereof.
13. The composition according to claim 12, which is selected from milk, yogurt, curd, cheese, fermented milks, milk based fermented products, ice-creams, fermented cereal based products, milk based powders, infant formulae, tablets, liquid bacterial suspensions, dried oral supplement, wet oral supplement, dry tube feeding or wet tube-feeding.



Nestlé Research Centre

Inhibition of adhesion of enterovirulent *E. coli* during the contact with the bacterial culture NCC2461




Fig. 1



Nestlé Research Centre

Inhibition of adhesion of enterovirulent *E. coli* during the contact with the supernatant of NCC2461




Fig.2



Nestlé Research Centre

Inhibition of invasion of *Salmonella* during the contact with the bacterial culture NCC2461




Fig.3



Nestlé Research Centre

Inhibition of invasion of *Salmonella typhimurium* during the contact with the supernatant of NCC2461




Fig.4

Fig. 5





Fig. 6

Survival in cereal drink



HDPE: High density poly ethylene

PS: polystyrene

Vit C: vitamin C

Fig.7

INDUCTION OF CYTOKINE mRNA BY LAB IN MOUSE MACROPHAGES





Fig.8

CYTOKINE RELEASE IN IVD 980916
(ELISA 981103 & 980925)



European Patent
Office

EUROPEAN SEARCH REPORT

Application Number
EP 99 10 4922

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
X,D	EP 0 577 903 A (NESTLE SA) 12 January 1994 (1994-01-12) * the whole document *	1,2,7-13	A61K35/74 C12N1/20 A23L1/29 A23C9/152 //(C12N1/20, C12R1:225)
X	WO 98 06411 A (DICOFARM SPA ;GUANDALINI STEFANO (IT)) 19 February 1998 (1998-02-19) * the whole document *	1-13	
X	US 5 837 238 A (MOLLSTAM BO ET AL) 17 November 1998 (1998-11-17) * the whole document *	1-3,7-13	
X	KAILA M ET AL: "VIABLE VERSUS INACTIVATED LACTOBACILLUS STRAIN GG IN ACUTE ROTAVIRUS DIARRHOEA" ARCHIVES OF DISEASE IN CHILDHOOD, vol. 72, no. 1, 1 January 1995 (1995-01-01), pages 51-53, XP002058045 * the whole document *	1-4,7-13	
X	EP 0 861 905 A (PROGE FARM S R L) 2 September 1998 (1998-09-02) * page 4, line 25 - page 5, line 35 *	1-13	
X	WO 95 33046 A (BRACCO SPA ;DIBRA SPA (IT); MORELLI LORENZO (IT); BOTTAZZI VITTORI) 7 December 1995 (1995-12-07) * page 9 - page 12 * * page 13 - page 27 *	1-13	
			TECHNICAL FIELDS SEARCHED (Int.Cl.7)
			A61K
The present search report has been drawn up for all claims			
Place of search THE HAGUE		Date of completion of the search 5 November 1999	Examiner Fernandez y Branas, F
CATEGORY OF CITED DOCUMENTS X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document			

EPO FORM 1503 03.82 (P/AC01)



European Patent
Office

EUROPEAN SEARCH REPORT

Application Number
EP 99 10 4922

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
X	TUOMOLA E.M. ET AL: "Adhesion of some probiotic and dairy Lactobacillus strains to Caco-2 cell cultures" INTERNATIONAL JOURNAL OF FOOD MICROBIOLOGY, vol. 41, 1998, pages 45-51, XP002115137 * the whole document *	1-13	
E	WO 99 29833 A (FONDEN RANGNE ;SVENSSON ULLA (SE); ALELJUNG PER (SE); ARLA EKONOMI) 17 June 1999 (1999-06-17) * the whole document *	1-5,7-13	
X	DATABASE BIOSIS 'Online! BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US PRASAD, JAYA ET AL: "Selection and characterisation of Lactobacillus and Bifidobacterium strains for use as probiotics." retrieved from STN XP002121832 * abstract * & INTERNATIONAL DAIRY JOURNAL, (1998) VOL. 8, NO. 12, PP. 993-1002. ,	1-4	
A	MIETTINEN, MINJA (1) ET AL: "Lactobacilli and streptococci induce interleukin-12 (IL-12), IL-18, and gamma interferon production in human peripheral blood mononuclear cells." INFECTION AND IMMUNITY, (DEC., 1998) VOL. 66, NO. 12, PP. 6058-6062. , XP002121831 * the whole document *	1-13	
The present search report has been drawn up for all claims			
Place of search THE HAGUE		Date of completion of the search 5 November 1999	Examiner Fernandez y Branas,F
<p>CATEGORY OF CITED DOCUMENTS</p> <p>X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document</p> <p>T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document</p>			

EPO FORM 1503 03 89 (Pdc011)

ANNEX TO THE EUROPEAN SEARCH REPORT
ON EUROPEAN PATENT APPLICATION NO.

EP 99 10 4922

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report. The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

05-11-1999

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 0577903 A	12-01-1994	AT 161181 T	15-01-1998
		AU 4158893 A	13-01-1994
		CA 2099855 A	07-01-1994
		CZ 9301342 A	19-01-1994
		DE 69223615 D	29-01-1998
		DE 69223615 T	09-04-1998
		DK 577903 T	06-04-1998
		ES 2111625 T	16-03-1998
		FI 933001 A	07-01-1994
		GR 3025971 T	30-04-1998
		HU 66632 A	28-12-1994
		JP 2672247 B	05-11-1997
		JP 6098782 A	12-04-1994
		NO 932407 A	07-01-1994
		NZ 248056 A	28-08-1995
		PL 299543 A	21-02-1994
		SK 71193 A	08-06-1994
		US 5578302 A	26-11-1996
WO 9806411 A	19-02-1998	IT RM960571 A	09-02-1998
		AU 3863997 A	06-03-1998
		EP 0918531 A	02-06-1999
US 5837238 A	17-11-1998	AU 3154897 A	05-01-1998
		EP 0923293 A	23-06-1999
		PL 330324 A	10-05-1999
		WO 9746104 A	11-12-1997
EP 0861905 A	02-09-1998	IT MI970426 A	27-08-1998
WO 9533046 A	07-12-1995	IT 1269838 B	15-04-1997
		IT 1274733 B	24-07-1997
		AT 163042 T	15-02-1998
		AU 686389 B	05-02-1998
		AU 2613995 A	21-12-1995
		BR 9507752 A	07-10-1997
		DE 69501591 D	12-03-1998
		DE 69501591 T	10-06-1998
		DE 760848 T	28-08-1997
		EP 0760848 A	12-03-1997
		ES 2099056 T	16-05-1997
		FI 964681 A	08-01-1997
		GR 97300016 T	31-05-1997
		GR 3026758 T	31-07-1998
		HU 75555 A	28-05-1997
		JP 10500577 T	20-01-1998

EPO FORM P0488

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82

**ANNEX TO THE EUROPEAN SEARCH REPORT
ON EUROPEAN PATENT APPLICATION NO.**

EP 99 10 4922

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report.
The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

05-11-1999

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9533046 A		NO 964966 A	23-01-1997
		NZ 287420 A	19-12-1997
		US 5709857 A	20-01-1998
WO 9929833 A	17-06-1999	SE 510813 C	28-06-1999
		AU 1896899 A	28-06-1999
		SE 9704577 A	09-06-1999

EPO FORM P0459

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

☐ BLACK BORDERS

☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES

☐ FADED TEXT OR DRAWING

☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING

☐ SKEWED/SLANTED IMAGES

☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS

☐ GRAY SCALE DOCUMENTS

☐ LINES OR MARKS ON ORIGINAL DOCUMENT

☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY

☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.